Search

Your search keyword '"Wall, Lucy"' showing total 130 results
Start Over Author "Wall, Lucy"
130 results on '"Wall, Lucy"'

1. Daily functioning in glioma survivors: associations with cognitive function, psychological factors and quality of life

Author

Van Dyk, Kathleen, Wall, Lucy, Heimberg, Brandon F, Choi, Justin, Raymond, Catalina, Wang, Chencai, Lai, Albert, Cloughesy, Timothy F, Ellingson, Benjamin M, and Nghiemphu, Phioanh

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Mental Illness, Depression, Brain Cancer, Mind and Body, Cancer, Brain Disorders, Behavioral and Social Science, Basic Behavioral and Social Science, Mental Health, Neurosciences, Neurodegenerative, Management of diseases and conditions, 7.1 Individual care needs, Mental health, Good Health and Well Being, Cognition, Cognition Disorders, Glioma, Humans, Quality of Life, Survivors, cancer, daily functioning, employment, function, glioma, quality of life, survivorship, Oncology and carcinogenesis
Abstract

Aim: Understanding and supporting quality of life (QoL) and daily functioning in glioma patients is a clinical imperative. In this study, we examined the relationship between cognition, psychological factors, measures of health-related QoL and functioning in glioma survivors. Materials & methods: We examined neuropsychological, self-reported cognition, mood and QoL correlates of work and non-work-related daily functioning in 23 glioma survivors, and carried out linear models of the best predictors. Results & conclusion: A total of 13/23 participants were working at the time of enrollment. The best model for worse work-related functioning (R2 = .83) included worse self-reported cognitive function, depression, loneliness and brain tumor symptoms. The best model for worse non-work-related functioning (R2 = .61) included worse self-reported cognitive functioning, anxiety, sleep disturbance and physical functioning. Neuropsychological variables were not among the most highly correlated with function. Worse cognitive, particularly self-reported and psychosocial outcomes may compromise optimal functioning in glioma survivors.

Published
2022

2. NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma

Author

McNamara, Mairéad G., Swain, Jayne, Craig, Zoe, Sharma, Rohini, Faluyi, Olusola, Wadsley, Jonathan, Morgan, Carys, Wall, Lucy R., Chau, Ian, Reed, Nick, Sarker, Debashis, Margetts, Jane, Krell, Daniel, Cave, Judith, Sothi, Sharmila, Anthoney, Alan, Bell, Christopher, Patel, Alkesh, Oughton, Jamie B., Cairns, David A., Mansoor, Wasat, Lamarca, Angela, Hubner, Richard A., and Valle, Juan W.

Published
2023
Full Text
View/download PDF

3. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study

Author

Primrose, JN, Fox, RP, Morement, H, Chan, O, Rees, C, Ma, YT, Hickish, T, Falk, S, Finch-Jones, M, Pope, I, Corrie, P, Crosby, T, Sothi, S, Sharkland, K, Adamson, D, Wall, L, Evans, J, Dent, J, Hombaiah, U, Iwuji, C, Anthoney, A, Bridgewater, J, Cunningham, D, Gillmore, R, Ross, P, Slater, S, Wasan, H, Waters, J, Valle, JW, Palmer, D, Malik, H, Neoptolemos, J, Faluyi, O, Sumpter, K, Dernedde, U, Maduhusudan, S, Cogill, G, Archer, C, Iveson, T, Wadsley, J, Darby, S, Peterson, M, Mukhtar, AA, Thorpe, JG, Bateman, A, Tsang, D, Cummins, S, Nolan, L, Beaumont, E, Prasad, R, Mirza, D, Stocken, D, Praseedom, R, Davidson, B, Raftery, J, Zhu, S, Garden, J, Stubbs, C, Coxon, F, Primrose, John N, Fox, Richard P, Palmer, Daniel H, Malik, Hassan Z, Prasad, Raj, Mirza, Darius, Anthony, Alan, Corrie, Pippa, Falk, Stephen, Finch-Jones, Meg, Wasan, Harpreet, Ross, Paul, Wall, Lucy, Wadsley, Jonathan, Evans, Jeff T R, Stocken, Deborah, Praseedom, Raaj, Ma, Yuk Ting, Davidson, Brian, Neoptolemos, John P, Iveson, Tim, Raftery, James, Zhu, Shihua, Cunningham, David, Garden, O James, Stubbs, Clive, Valle, Juan W, and Bridgewater, John

Published
2019
Full Text
View/download PDF

6. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial

Author

Meyer, Tim, Fox, Richard, Ma, Yuk Ting, Ross, Paul J, James, Martin W, Sturgess, Richard, Stubbs, Clive, Stocken, Deborah D, Wall, Lucy, Watkinson, Anthony, Hacking, Nigel, Evans, T R Jeffry, Collins, Peter, Hubner, Richard A, Cunningham, David, Primrose, John Neil, Johnson, Philip J, and Palmer, Daniel H

Published
2017
Full Text
View/download PDF

10. NET-02 final results: A randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (PD-EP-NEC).

Author

McNamara, Mairead Geraldine, primary, Swain, Jayne, additional, Craig, Zoe, additional, Sharma, Rohini, additional, Faluyi, Olusola Olusesan, additional, Wadsley, Jonathan, additional, Morgan, Carys, additional, Wall, Lucy R., additional, Chau, Ian, additional, Reed, Nick, additional, Sarker, Debashis, additional, Margetts, Jane, additional, Krell, Daniel, additional, Cave, Judith, additional, Sharmila, Sothi, additional, Anthoney, Alan, additional, Patel, Alkesh, additional, Lamarca, Angela, additional, Hubner, Richard, additional, and Valle, Juan W., additional

Published
2023
Full Text
View/download PDF

15. Advance care planning in primary care for cancer patients:Feasibility randomised trial

Author

Canny, Anne, Mason, Bruce, Stephen, Jacqueline, Hopkins, Samantha, Wall, Lucy, Christie, Alan, Skipworth, Richard, Bowden, Joanna, Graham, Louise, Kendall, Marilyn, Weir, Christopher J, and Boyd, Kirsty

Subjects
primary health care, general practice, mixed methods research, anticipatory care planning, cancer, advance care planning
Abstract

BACKGROUND: Advance (anticipatory) care planning (ACP) requires discussions between patients and healthcare professionals about planning for future deterioration in health. ACP improves care coordination but uptake is limited and often deferred.AIM: To assess the feasibility and acceptability to patients, carers, and GPs of a primary care ACP intervention for people with incurable oesophageal, gastric, or pancreatic cancer.DESIGN AND SETTING: A 12-month feasibility randomised controlled trial (RCT) in a Scottish Cancer Network.METHOD: Patients aged ≥18 years starting palliative oncology treatment were randomised 1:1 to an ACP intervention or standard care. Patients in the intervention group received an oncologist letter supporting them to request a GP review along with a patient information leaflet about ACP. Pre-specified analyses with masking included trial recruitment and retention, ACP completion, and quality-of-life questionnaires (EuroQol EQ-5D-5L and ICECAP Supportive Care Measure) at baseline, 6, 12, 24, and 48 weeks. Qualitative interviews with purposive sampling explored patient, carer, and GP experiences.RESULTS: Of 99 eligible participants (269 screened), 46% were recruited ( n = 46) and randomised; 25 to intervention and 21 to control. By 12 weeks, 45% ( n = 9/20) of the individuals in the intervention and 59% ( n = 10/17) in the control group had a documented ACP plan. By 24 weeks, 30% ( n = 14) had died; in the remaining participants quality of life was maintained at 24 weeks except for physical symptoms. Social norms associating ACP with dying were prevalent among 23 participants interviewed. No psychological or clinical harms were identified. CONCLUSION: An RCT of ACP for people with incurable cancer in primary care is feasible. Patient, carer, and GP attitudes and behaviours determined acceptability and timing of care planning.

Published
2022
Full Text
View/download PDF

17. NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).

Author

McNamara, Mairead Geraldine, primary, Swain, Jayne, additional, Craig, Zoe, additional, Sharma, Rohini, additional, Faluyi, Olusola Olusesan, additional, Wadsley, Jonathan, additional, Morgan, Carys, additional, Wall, Lucy R., additional, Chau, Ian, additional, Reed, Nick, additional, Sarker, Debashis, additional, Margetts, Jane, additional, Krell, Daniel, additional, Cave, Judith, additional, Sharmila, Sothi, additional, Anthoney, Alan, additional, Patel, Alkesh, additional, Lamarca, Angela, additional, Hubner, Richard A, additional, and Valle, Juan W., additional

Published
2022
Full Text
View/download PDF

18. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study

Author

Bridgewater, John, Fletcher, Peter, Palmer, Daniel H., Malik, Hassan Z., Prasad, Raj, Mirza, Darius, Anthony, Alan, Corrie, Pippa, Falk, Stephen, Finch-Jones, Meg, Wasan, Harpreet, Ross, Paul, Wall, Lucy, Wadsley, Jonathan, Evans, Thomas R., Stocken, Deborah, Stubbs, Clive, Praseedom, Raaj, Ma, Yuk Ting, Davidson, Brian, Neoptolemos, John, Iveson, Tim, Cunningham, David, Garden, O. James, Valle, Juan W., and Primrose, John

Subjects
Biliary Tract Neoplasms/drug therapy, Cancer Research, Adolescent, Manchester Cancer Research Centre, Oncology, Chemotherapy, Adjuvant, ResearchInstitutes_Networks_Beacons/mcrc, Humans, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Prognosis, Capecitabine
Abstract

PURPOSE The BILCAP study described a modest benefit for capecitabine as adjuvant therapy for curatively resected biliary tract cancer (BTC), and capecitabine has become the standard of care. We present the long-term data and novel exploratory subgroup analyses. METHODS This randomized, controlled, multicenter, phase III study recruited patients age 18 years or older with histologically confirmed cholangiocarcinoma or muscle-invasive gallbladder cancer after resection with curative intent and an Eastern Cooperative Oncology Group performance status of < 2. Patients were randomly assigned 1:1 to receive oral capecitabine (1,250 mg/m2 twice daily on days 1-14 of a 21-day cycle, for eight cycles) or observation. The primary outcome was overall survival (OS). This study is registered with EudraCT 2005-003318-13. RESULTS Between March 15, 2006, and December 4, 2014, 447 patients were enrolled; 223 patients with BTC resected with curative intent were randomly assigned to the capecitabine group and 224 to the observation group. At the data cutoff of January 21, 2021, the median follow-up for all patients was 106 months (95% CI, 98 to 108). In the intention-to-treat analysis, the median OS was 49.6 months (95% CI, 35.1 to 59.1) in the capecitabine group compared with 36.1 months (95% CI, 29.7 to 44.2) in the observation group (adjusted hazard ratio 0.84; 95% CI, 0.67 to 1.06). In a protocol-specified sensitivity analysis, adjusting for minimization factors, nodal status, grade, and sex, the OS hazard ratio was 0.74 (95% CI, 0.59 to 0.94). We further describe the prognostic impact of R status, grade, nodal status, and sex. CONCLUSION This long-term analysis supports the previous analysis, suggesting that capecitabine can improve OS in patients with resected BTC when used as adjuvant chemotherapy after surgery and should be considered as the standard of care.

Published
2022
Full Text
View/download PDF

20. Advance care planning in primary care for patients with gastrointestinal cancer: feasibility randomised trial

Author

Canny, Anne, primary, Mason, Bruce, additional, Stephen, Jacqueline, additional, Hopkins, Samantha, additional, Wall, Lucy, additional, Christie, Alan, additional, Skipworth, Richard JE, additional, Bowden, Joanna, additional, Graham, Louise, additional, Kendall, Marilyn, additional, Weir, Christopher J, additional, and Boyd, Kirsty, additional

Published
2022
Full Text
View/download PDF

22. Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

Author

Caplin, Martyn E., Pavel, Marianne, Ćwikła, Jarosław B., Phan, Alexandria T., Raderer, Markus, Sedláčková, Eva, Cadiot, Guillaume, Wolin, Edward M., Capdevila, Jaume, Wall, Lucy, Rindi, Guido, Langley, Alison, Martinez, Séverine, Blumberg, Joëlle, and Ruszniewski, Philippe

Published
2014
Full Text
View/download PDF

23. Long Term Outcomes and Exploratory Analyses of the Randomised Phase 3 BILCAP Study

Author

Bridgewater, John, primary, Fletcher, Peter, additional, Palmer, Daniel, additional, Malik, Hassan, additional, Prasad, Raj, additional, Mirza, Darius, additional, Anthoney, Alan, additional, Corrie, Pippa, additional, Falk, Steven, additional, Finch-Jones, Meg, additional, Wasan, Harpreet, additional, Ross, Paul, additional, wall, lucy, additional, Wadsley, Jonathan, additional, Evans, Jeff, additional, Stocken, Deborah D., additional, Stubbs, Clive, additional, Praseedom, Raaj, additional, Ma, Yuk Ting, additional, Davidson, Brian, additional, Neoptolemos, John, additional, Iveson, Tim, additional, Cunningham, David, additional, Garden, James, additional, Valle, Juan, additional, and Primrose, John, additional

Published
2021
Full Text
View/download PDF

28. NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)

Author

Craig, Zoe, primary, Swain, Jayne, additional, Batman, Emma, additional, Wadsley, Jonathan, additional, Reed, Nicholas, additional, Faluyi, Olusola, additional, Cave, Judith, additional, Sharma, Rohini, additional, Chau, Ian, additional, Wall, Lucy, additional, Lamarca, Angela, additional, Hubner, R, additional, Mansoor, Wasat, additional, Sarker, Debashis, additional, Meyer, Tim, additional, Cairns, David A, additional, Howard, Helen, additional, Valle, Juan W, additional, and McNamara, Mairéad G, additional

Published
2020
Full Text
View/download PDF

29. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial

Author

Jones, Robert P, Psarelli, Eftychia-Eirini, Jackson, Richard, Ghaneh, Paula, Halloran, Christopher M, Palmer, Daniel H, Campbell, Fiona, Valle, Juan W, Faluyi, Olusola, O'Reilly, Derek A, Cunningham, David, Wadsley, Jonathan, Darby, Suzanne, Meyer, Tim, Gillmore, Roopinder, Anthoney, Alan, Lind, Pehr, Glimelius, Bengt, Falk, Stephen, Izbicki, Jakob R, Middleton, Gary William, Cummins, Sebastian, Ross, Paul J, Wasan, Harpreet, McDonald, Alec, Crosby, Tom, Ting, Yuk, Patel, Kinnari, Sherriff, David, Soomal, Rubin, Borg, David, Sothi, Sharmila, Hammel, Pascal, Lerch, Markus M, Mayerle, Julia, Tjaden, Christine, Strobel, Oliver, Hackert, Thilo, Buchler, Markus W, Neoptolemos, John P, Hill, Mark, Corrie, Pippa, Hickish, Tamas, Napier, Mark, Slater, Sarah, Valle, Juan, Shablak, Alaaeldin, Cunnell, Michelle, Guimbaud, Rosine, Roques, Tom, Iveson, Tim, Jamil, Arshad, Robinson, Angus, Garcia-Alonso, Angel, Chang, David, Tsang, David, Wadd, Nick, Wall, Lucy, Nielsen, Niels Hilmer, Lerch, Markus, Mehta, Ajay, Sivaramalingam, Muthiah, Fyfe, David, Osborne, Richard, Blesing, Claire, Bulusu, Venkata Ramesh, Rathbone, Emma, Seitz, Jean-Francois, Beaumont, Erica, Dernedde, Ulrike, McAdam, Karen, Dimopoulos, Prokopios, Cominos, Mathilda, Askill, Colin, Piwowar, Andrzej, Bachet, Jean-Baptiste, Sumpter, Kate, Raouf, Sherif, Nicoll, Jonathan, Rees, Charlotte, Dhinakaran, Kathirvelu, Haux, Johan, Bengrine-Lefevre, Leila, Terrebonne, Eric, Shankland, Catherine, Palmer, Cheryl, Medley, Louise, Toy, Elizabeth, Kaur, Jasvinder, Gupta, Kamalnayan, Cheeseman, Sue, Patterson, Daniel, Candish, Charles, Thompson, Joyce, Coxon, Fareeda, Connolly, Caroline, McPhail, Neil, Williams, Rachel, Flygare, Petra, Elmlund, Mattias, Artru, Pascal, Millat, Bertrand, and Canc, European Study Grp Pancreatic

Subjects
medicine.medical_specialty, Chemotherapy, Randomization, business.industry, medicine.medical_treatment, 030230 surgery, medicine.disease, Gastroenterology, Gemcitabine, law.invention, Capecitabine, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, 030220 oncology & carcinogenesis, Internal medicine, Pancreatic cancer, medicine, Carcinoma, Surgery, Prospective cohort study, business, medicine.drug
Abstract

Importance The patterns of disease recurrence after resection of pancreatic ductal adenocarcinoma with adjuvant chemotherapy remain unclear. Objective To define patterns of recurrence after adjuvant chemotherapy and the association with survival. Design, Setting, and Participants Prospectively collected data from the phase 3 European Study Group for Pancreatic Cancer 4 adjuvant clinical trial, an international multicenter study. The study included 730 patients who had resection and adjuvant chemotherapy for pancreatic cancer. Data were analyzed between July 2017 and May 2019. Interventions Randomization to adjuvant gemcitabine or gemcitabine plus capecitabine. Main Outcomes and Measures Overall survival, recurrence, and sites of recurrence. Results Of the 730 patients, median age was 65 years (range 37-81 years), 414 were men (57%), and 316 were women (43%). The median follow-up time from randomization was 43.2 months (95% CI, 39.7-45.5 months), with overall survival from time of surgery of 27.9 months (95% CI, 24.8-29.9 months) with gemcitabine and 30.2 months (95% CI, 25.8-33.5 months) with the combination (HR, 0.81; 95% CI, 0.68-0.98;P = .03). The 5-year survival estimates were 17.1% (95% CI, 11.6%-23.5%) and 28.0% (22.0%-34.3%), respectively. Recurrence occurred in 479 patients (65.6%); another 78 patients (10.7%) died without recurrence. Local recurrence occurred at a median of 11.63 months (95% CI, 10.05-12.19 months), significantly different from those with distant recurrence with a median of 9.49 months (95% CI, 8.44-10.71 months) (HR, 1.21; 95% CI, 1.01-1.45;P = .04). Following recurrence, the median survival was 9.36 months (95% CI, 8.08-10.48 months) for local recurrence and 8.94 months (95% CI, 7.82-11.17 months) with distant recurrence (HR, 0.89; 95% CI, 0.73-1.09;P = .27). The median overall survival of patients with distant-only recurrence (23.03 months; 95% CI, 19.55-25.85 months) or local with distant recurrence (23.82 months; 95% CI, 17.48-28.32 months) was not significantly different from those with only local recurrence (24.83 months; 95% CI, 22.96-27.63 months) (P = .85 andP = .35, respectively). Gemcitabine plus capecitabine had a 21% reduction of death following recurrence compared with monotherapy (HR, 0.79; 95% CI, 0.64-0.98;P = .03). Conclusions and Relevance There were no significant differences between the time to recurrence and subsequent and overall survival between local and distant recurrence. Pancreatic cancer behaves as a systemic disease requiring effective systemic therapy after resection. Trial Registration ClinicalTrials.gov identifier:NCT00058201, EudraCT 2007-004299-38, and ISRCTN 96397434.

Published
2019

30. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma : A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial

Author

Jones, Robert P., Psarelli, Eftychia-Eirini, Jackson, Richard, Ghaneh, Paula, Halloran, Christopher M., Palmer, Daniel H., Campbell, Fiona, Valle, Juan W., Faluyi, Olusola, O'Reilly, Derek A., Cunningham, David, Wadsley, Jonathan, Darby, Suzanne, Meyer, Tim, Gillmore, Roopinder, Anthoney, Alan, Lind, Pehr, Glimelius, Bengt, Falk, Stephen, Izbicki, Jakob R., Middleton, Gary William, Cummins, Sebastian, Ross, Paul J., Wasan, Harpreet, McDonald, Alec, Crosby, Tom, Ting, Yuk, Patel, Kinnari, Sherriff, David, Soomal, Rubin, Borg, David, Sothi, Sharmila, Hammel, Pascal, Lerch, Markus M., Mayerle, Julia, Tjaden, Christine, Strobel, Oliver, Hackert, Thilo, Buchler, Markus W., Neoptolemos, John P., Hill, Mark, Corrie, Pippa, Hickish, Tamas, Napier, Mark, Slater, Sarah, Valle, Juan, Shablak, Alaaeldin, Cunnell, Michelle, Guimbaud, Rosine, Roques, Tom, Iveson, Tim, Jamil, Arshad, Robinson, Angus, Garcia-Alonso, Angel, Chang, David, Tsang, David, Wadd, Nick, Wall, Lucy, Nielsen, Niels Hilmer, Lerch, Markus, Mehta, Ajay, Sivaramalingam, Muthiah, Fyfe, David, Osborne, Richard, Blesing, Claire, Bulusu, Venkata Ramesh, Rathbone, Emma, Seitz, Jean-Francois, Beaumont, Erica, Dernedde, Ulrike, McAdam, Karen, Dimopoulos, Prokopios, Cominos, Mathilda, Askill, Colin, Piwowar, Andrzej, Bachet, Jean-Baptiste, Sumpter, Kate, Raouf, Sherif, Nicoll, Jonathan, Rees, Charlotte, Dhinakaran, Kathirvelu, Haux, Johan, Bengrine-Lefevre, Leila, Terrebonne, Eric, Shankland, Catherine, Palmer, Cheryl, Medley, Louise, Toy, Elizabeth, Kaur, Jasvinder, Gupta, Kamalnayan, Cheeseman, Sue, Patterson, Daniel, Candish, Charles, Thompson, Joyce, Coxon, Fareeda, Connolly, Caroline, McPhail, Neil, Williams, Rachel, Flygare, Petra, Elmlund, Mattias, Artru, Pascal, Millat, Bertrand, Jones, Robert P., Psarelli, Eftychia-Eirini, Jackson, Richard, Ghaneh, Paula, Halloran, Christopher M., Palmer, Daniel H., Campbell, Fiona, Valle, Juan W., Faluyi, Olusola, O'Reilly, Derek A., Cunningham, David, Wadsley, Jonathan, Darby, Suzanne, Meyer, Tim, Gillmore, Roopinder, Anthoney, Alan, Lind, Pehr, Glimelius, Bengt, Falk, Stephen, Izbicki, Jakob R., Middleton, Gary William, Cummins, Sebastian, Ross, Paul J., Wasan, Harpreet, McDonald, Alec, Crosby, Tom, Ting, Yuk, Patel, Kinnari, Sherriff, David, Soomal, Rubin, Borg, David, Sothi, Sharmila, Hammel, Pascal, Lerch, Markus M., Mayerle, Julia, Tjaden, Christine, Strobel, Oliver, Hackert, Thilo, Buchler, Markus W., Neoptolemos, John P., Hill, Mark, Corrie, Pippa, Hickish, Tamas, Napier, Mark, Slater, Sarah, Valle, Juan, Shablak, Alaaeldin, Cunnell, Michelle, Guimbaud, Rosine, Roques, Tom, Iveson, Tim, Jamil, Arshad, Robinson, Angus, Garcia-Alonso, Angel, Chang, David, Tsang, David, Wadd, Nick, Wall, Lucy, Nielsen, Niels Hilmer, Lerch, Markus, Mehta, Ajay, Sivaramalingam, Muthiah, Fyfe, David, Osborne, Richard, Blesing, Claire, Bulusu, Venkata Ramesh, Rathbone, Emma, Seitz, Jean-Francois, Beaumont, Erica, Dernedde, Ulrike, McAdam, Karen, Dimopoulos, Prokopios, Cominos, Mathilda, Askill, Colin, Piwowar, Andrzej, Bachet, Jean-Baptiste, Sumpter, Kate, Raouf, Sherif, Nicoll, Jonathan, Rees, Charlotte, Dhinakaran, Kathirvelu, Haux, Johan, Bengrine-Lefevre, Leila, Terrebonne, Eric, Shankland, Catherine, Palmer, Cheryl, Medley, Louise, Toy, Elizabeth, Kaur, Jasvinder, Gupta, Kamalnayan, Cheeseman, Sue, Patterson, Daniel, Candish, Charles, Thompson, Joyce, Coxon, Fareeda, Connolly, Caroline, McPhail, Neil, Williams, Rachel, Flygare, Petra, Elmlund, Mattias, Artru, Pascal, and Millat, Bertrand

Abstract

Importance: The patterns of disease recurrence after resection of pancreatic ductal adenocarcinoma with adjuvant chemotherapy remain unclear. Objective: To define patterns of recurrence after adjuvant chemotherapy and the association with survival. Design, Setting, and Participants: Prospectively collected data from the phase 3 European Study Group for Pancreatic Cancer 4 adjuvant clinical trial, an international multicenter study. The study included 730 patients who had resection and adjuvant chemotherapy for pancreatic cancer. Data were analyzed between July 2017 and May 2019. Interventions: Randomization to adjuvant gemcitabine or gemcitabine plus capecitabine. Main Outcomes and Measures: Overall survival, recurrence, and sites of recurrence. Results: Of the 730 patients, median age was 65 years (range 37-81 years), 414 were men (57%), and 316 were women (43%). The median follow-up time from randomization was 43.2 months (95% CI, 39.7-45.5 months), with overall survival from time of surgery of 27.9 months (95% CI, 24.8-29.9 months) with gemcitabine and 30.2 months (95% CI, 25.8-33.5 months) with the combination (HR, 0.81; 95% CI, 0.68-0.98; P=.03). The 5-year survival estimates were 17.1% (95% CI, 11.6%-23.5%) and 28.0% (22.0%-34.3%), respectively. Recurrence occurred in 479 patients (65.6%); another 78 patients (10.7%) died without recurrence. Local recurrence occurred at a median of 11.63 months (95% CI, 10.05-12.19 months), significantly different from those with distant recurrence with a median of 9.49 months (95% CI, 8.44-10.71 months) (HR, 1.21; 95% CI, 1.01-1.45; P=.04). Following recurrence, the median survival was 9.36 months (95% CI, 8.08-10.48 months) for local recurrence and 8.94 months (95% CI, 7.82-11.17 months) with distant recurrence (HR, 0.89; 95% CI, 0.73-1.09; P=.27). The median overall survival of patients with distant-only recurrence (23.03 months; 95% CI, 19.55-25.85 months) or local with distant recurrence (23.82 months; 95% CI, 17.48-28.32

Published
2019
Full Text
View/download PDF

35. A lab sciences camp for high schoolers

Author

Thompson, Janet L., Knebel, Patricia, and Wall, Lucy J.

Subjects
Medical technologists -- Practice, School camps -- Evaluation, Medical technology -- Vocational guidance
Abstract

Members of the Iowa Society for Medical Technology (ISMT) first organized Laboratory Pursuits, a clinical laboratory sciences camp for high schoolers, in 1990. This science camp was the result of a cooperati ve effort among ISMT, industry, the professional community and Wartburg College, IA, where the camp was held. From the very beginning, the camp proved to be a rewarding experience for all concerned. As a result, the camp is now in its third season, with total costs for each camper set at $105.

Published
1993

36. NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/ folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC).

Author

Craig, Zoe, Swain, Jayne, Batman, Emma, Wadsley, Jonathan, Reed, Nicholas, Faluyi, Olusola, Cave, Judith, Sharma, Rohini, Chau, Ian, Wall, Lucy, Lamarca, Angela, Hubner, R., Mansoor, Wasat, Sarker, Debashis, Meyer, Tim, Cairns, David A., Howard, Helen, Valle, Juan W., and McNamara, Mairéad G.

Abstract

Introduction Poorly differentiated (PD), extrapulmonary (EP), neuroendocrine carcinomas (NECs) are rare but aggressive neuroendocrine neoplasms. First-line treatment for advanced disease is an etoposide and platinum-based chemotherapy combination. There is no established second-line treatment for patients with PD-EP-NEC, and this is an area of unmet need. Methods and analysis NET-02 is a UK, multicentre, randomised (1:1), parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive PD-EP-NEC. One hundred and two eligible participants will be randomised to receive either nal-IRI/5-FU/folinic acid or docetaxel. The primary objective is to determine the 6-month progression-free survival (PFS) rate. The secondary objectives of this study are to determine PFS, overall survival, objective response rate, toxicity, quality of life and whether neuron-specific enolase is predictive of treatment response. If either treatment is found to have a 6-month PFS rate of at least 25%, that treatment will be considered for a phase III trial. If both treatments meet this target, prespecified selection criteria will be applied to establish which treatment to take forward. Ethics and dissemination This study has ethical approval from the Greater Manchester Central Research Ethics Committee (reference no. 18/NW/0031) and clinical trial authorisation from the Medicine and Healthcare Products Regulatory Agency. Results will be published in peer-reviewed journals and uploaded to the European Union Clinical Trials Register. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

37. Patterns of recurrence after curative-intent surgery for pancreas cancer reinforce the importance of locoregional control and adjuvant chemotherapy

Author

Munir, Rohan, primary, Soreide, Kjetil, additional, Ravindran, Rajan, additional, Powell, James J., additional, Harrison, Ewen M., additional, Adair, Anya, additional, Wigmore, Stephen J., additional, Parks, Rowan W., additional, Garden, O. James, additional, Kirkpatrick, Lorraine, additional, Wall, Lucy R, additional, Christie, Alan, additional, Penman, Ian, additional, McAvoy, Norma, additional, Save, Vicki, additional, Stockman, Alan, additional, Worrall, David, additional, Ireland, Hamish, additional, Weir, Graeme, additional, Masson, Neil, additional, Hay, Chris, additional, Smith, James-Gordon, additional, and Mole, Damian J., additional

Published
2018
Full Text
View/download PDF

39. Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.

Author

Primrose, John Neil, primary, Fox, Richard, additional, Palmer, Daniel H., additional, Prasad, Raj, additional, Mirza, Darius, additional, Anthoney, David Alan, additional, Corrie, Philippa, additional, Falk, Stephen, additional, Wasan, Harpreet Singh, additional, Ross, Paul J., additional, Wall, Lucy R., additional, Wadsley, Jonathan, additional, Evans, T.R. Jeffry, additional, Stocken, Deborah, additional, Praseedom, Raaj, additional, Cunningham, David, additional, Garden, O James, additional, Stubbs, Clive, additional, Valle, Juan W., additional, and Bridgewater, John A., additional

Published
2017
Full Text
View/download PDF

41. UK Phase IV, Observational study to assess Quality of Life in patients (pts) with pancreatic neuroendocrine tumours (pNETs) receiving treatment with Everolimus: The “Real-World” OBLIQUE Study

Author

Ramage, John, primary, Punia, Pankaj, additional, Olusola, Faluyi, additional, Frilling, Andrea, additional, Meyer, Tim, additional, Kapur, Gaurav, additional, Cave, Judith, additional, Wadsley, Johnathan, additional, Cummins, Sebastian, additional, Farrugia, David, additional, Starling, Naureen, additional, Wall, Lucy, additional, Saharan, Ruby, additional, and Valle, Juan, additional

Published
2016
Full Text
View/download PDF

42. TACE 2: A randomized placebo-controlled, double-blinded, phase III trial evaluating sorafenib in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma (HCC)—Background.

Author

Meyer, Tim, primary, Fox, Richard, additional, Ma, Yuk Ting, additional, Ross, Paul J., additional, James, Martin, additional, Strugess, Richard, additional, Stubbs, Clive, additional, Wall, Lucy, additional, Watkinson, Anthony, additional, Hacking, Nigel, additional, Evans, T.R. Jeffry, additional, Collins, Peter, additional, Hubner, Richard, additional, Cunningham, David, additional, Primrose, John Neil, additional, Johnson, Philip James, additional, and Palmer, Daniel H., additional

Published
2016
Full Text
View/download PDF

43. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study

Author

Caplin, Martyn E, primary, Pavel, Marianne, additional, Ćwikła, Jarosław B, additional, Phan, Alexandria T, additional, Raderer, Markus, additional, Sedláčková, Eva, additional, Cadiot, Guillaume, additional, Wolin, Edward M, additional, Capdevila, Jaume, additional, Wall, Lucy, additional, Rindi, Guido, additional, Langley, Alison, additional, Martinez, Séverine, additional, Gomez-Panzani, Edda, additional, Ruszniewski, Philippe, additional, and _, _, additional

Published
2016
Full Text
View/download PDF

44. Antiproliferative effects of lanreotide Autogel in patients with enteropancreatic neuroendocrine tumours: results of CLARINET, a large international phase 3 study

Author

Caplin, Martyn, primary, Ruszniewski, Philippe, additional, Pavel, Marianne, additional, Cwikla, Jaroslaw, additional, Phan, Alexandria, additional, Raderer, Markus, additional, Sedlackova, Eva, additional, Cadiot, Guillaume, additional, Wall, Lucy, additional, Rindi, Guido, additional, Langley, Alison, additional, and Blumberg, Joelle, additional

Published
2014
Full Text
View/download PDF

45. Physical Activity Monitoring: A Responsive and Meaningful Patient-Centered Outcome for Surgery, Chemotherapy, or Radiotherapy?

Author

Ferriolli, Eduardo, primary, Skipworth, Richard J.E., additional, Hendry, Paul, additional, Scott, Angela, additional, Stensteth, Jacob, additional, Dahele, Max, additional, Wall, Lucy, additional, Greig, Carolyn, additional, Fallon, Marie, additional, Strasser, Florian, additional, Preston, Tom, additional, and Fearon, Kenneth C.H., additional

Published
2012
Full Text
View/download PDF

46. Screening for major depression in cancer outpatients

Author

Thekkumpurath, Parvez, primary, Walker, Jane, additional, Butcher, Isabella, additional, Hodges, Laura, additional, Kleiboer, Annet, additional, O'Connor, Mark, additional, Wall, Lucy, additional, Murray, Gordon, additional, Kroenke, Kurt, additional, and Sharpe, Michael, additional

Published
2010
Full Text
View/download PDF

47. Health-related quality of life (HRQoL) in patients (pts) with progressive, poorly differentiated, extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) enrolled in NET-02: A phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil...

Author

Craig, Zoe, Swain, Jayne, Sharma, Rohini, Faluyi, Olusola Olusesan, Wadsley, Jonathan, Morgan, Carys, Wall, Lucy R., Chau, Ian, Reed, Nicholas Simon, Sarker, Debashis, Margetts, Jane, Krell, Daniel, Cave, Judith, Sharmila, Sothi, Anthoney, Alan, Patel, Alkesh, Lamarca, Angela, Hubner, Richard A, Valle, Juan W., and McNamara, Mairead Geraldine

Published
2022
Full Text
View/download PDF

48. Better Off Dead: Suicidal Thoughts in Cancer Patients

Author

Walker, Jane, primary, Waters, Rachel A., additional, Murray, Gordon, additional, Swanson, Helen, additional, Hibberd, Carina J., additional, Rush, Robert W., additional, Storey, Dawn J., additional, Strong, Vanessa A., additional, Fallon, Marie T., additional, Wall, Lucy R., additional, and Sharpe, Michael, additional

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results